

Worldwide, colorectal cancer is the second leading cause of cancer-related mortality and the third most common cancer, with incidence rates increasing among individuals younger than 50 years.1 Although there are multiple effective colorectal cancer screening modalities, uptake is variable. Disparities in screening participation are driven, in part, by social determinants of health, including educational attainment, income, and living environment. For example, in the USA, screening rates are lowest among non-White individuals, the uninsured, those with low income, and individuals without a high school degree.
Gastroenterology & Hepatology
|15th Jan, 2026
|The Lancet
Gastroenterology & Hepatology
|15th Jan, 2026
|The Lancet
Gastroenterology & Hepatology
|15th Jan, 2026
|The Lancet
Gastroenterology & Hepatology
|15th Jan, 2026
|The Lancet
Gastroenterology & Hepatology
|15th Jan, 2026
|The Lancet
Gastroenterology & Hepatology
|15th Jan, 2026
|The Lancet
Gastroenterology & Hepatology
|15th Jan, 2026
|The Lancet